Tauopathy-focused Asceneuron secures $30m
This article was originally published in Scrip
Executive Summary
Asceneuron, a startup biotech company with ambitions to take the lead in neurodegeneration drug development, has managed to secure CHF30m (US$30.6m) to advance its tauopathy drug. Investors have clearly seen potential in the company despite a lack of clarity on the relationship between the tau protein and neurodegeneration.